These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Effects of pioglitazone on lipid and lipoprotein metabolism. Betteridge DJ Diabetes Obes Metab; 2007 Sep; 9(5):640-7. PubMed ID: 17697057 [TBL] [Abstract][Full Text] [Related]
5. The safety and efficacy of achieving very low LDL-cholesterol concentrations with high dose statin therapy. Wiviott SD; Cannon CP Curr Opin Lipidol; 2006 Dec; 17(6):626-30. PubMed ID: 17095906 [TBL] [Abstract][Full Text] [Related]
6. Lipid-lowering therapy in patients with type 2 diabetes: the case for early intervention. Steinmetz A Diabetes Metab Res Rev; 2008; 24(4):286-93. PubMed ID: 18273835 [TBL] [Abstract][Full Text] [Related]
7. Low plasma HDL-c, a vascular risk factor in high risk patients independent of LDL-c. Hajer GR; van der Graaf Y; Bots ML; Algra A; Visseren FL; Eur J Clin Invest; 2009 Aug; 39(8):680-8. PubMed ID: 19453647 [TBL] [Abstract][Full Text] [Related]
11. Beyond LDL cholesterol: the role of elevated triglycerides and low HDL cholesterol in residual CVD risk remaining after statin therapy. Alagona P Am J Manag Care; 2009 Mar; 15(3 Suppl):S65-73. PubMed ID: 19355805 [TBL] [Abstract][Full Text] [Related]
12. Model-based simulation to explore the cost-effectiveness of following practice guidelines for triglyceride and low-density lipoprotein cholesterol control among patients with diabetes mellitus and mixed dyslipidemia. Sorensen SV; Frick KD; Wade A; Simko R; Burge R Clin Ther; 2009 Apr; 31(4):862-79. PubMed ID: 19446159 [TBL] [Abstract][Full Text] [Related]
13. Long-term lipid effects of pioglitazone by baseline anti-hyperglycemia medication therapy and statin use from the PROactive experience (PROactive 14). Spanheimer R; Betteridge DJ; Tan MH; Ferrannini E; Charbonnel B; Am J Cardiol; 2009 Jul; 104(2):234-9. PubMed ID: 19576353 [TBL] [Abstract][Full Text] [Related]
15. Statins: are any questions unanswered? Kearney PM; Baigent C Curr Opin Lipidol; 2006 Aug; 17(4):418-25. PubMed ID: 16832166 [TBL] [Abstract][Full Text] [Related]
16. Low- and high-density lipoprotein cholesterol goal attainment in dyslipidemic women: The Lipid Treatment Assessment Project (L-TAP) 2. Santos RD; Waters DD; Tarasenko L; Messig M; Jukema JW; Ferrières J; Verdejo J; Chiang CW; Am Heart J; 2009 Nov; 158(5):860-6. PubMed ID: 19853709 [TBL] [Abstract][Full Text] [Related]
17. Relation of clinical benefit of raising high-density lipoprotein cholesterol to serum levels of low-density lipoprotein cholesterol in patients with coronary heart disease (from the Bezafibrate Infarction Prevention Trial). Goldenberg I; Benderly M; Sidi R; Boyko V; Tenenbaum A; Tanne D; Behar S Am J Cardiol; 2009 Jan; 103(1):41-5. PubMed ID: 19101227 [TBL] [Abstract][Full Text] [Related]
18. Fenofibrate and rosiglitazone improve quality of lipoproteins in patients with type 2 diabetes mellitus. Vrablík M; Dobiásová M; Stulc T; Kasalová Z; Dolezalová R; Prázný M; Fait T; Ceska R Neuro Endocrinol Lett; 2008 Feb; 29(1):146-50. PubMed ID: 18283261 [TBL] [Abstract][Full Text] [Related]
19. Expert perspective: reducing cardiovascular risk in metabolic syndrome and type 2 diabetes mellitus beyond low-density lipoprotein cholesterol lowering. Jones PH Am J Cardiol; 2008 Dec; 102(12A):41L-47L. PubMed ID: 19084089 [TBL] [Abstract][Full Text] [Related]
20. The rough road for rosiglitazone. Goldfine AB Curr Opin Endocrinol Diabetes Obes; 2008 Apr; 15(2):113-7. PubMed ID: 18316944 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]